Lance Platform

SEVEN NOVEL IMMUNOMETABOLIC TARGETS

Omilancor
Discovery
IND
Initiation of
Phase 1
Phase 2
Phase 3
ready
24 Months
30 Months
NX-13
LABP-104
LABP-111
LABP-66
LABP-69
LABP-73
Discovery
IND
Initiation of
Phase 1
Phase 2
ready
Phase 3
18 Months
(for NX-13, all others projected)
24 Months
(projected)